Literature DB >> 2173527

Reactivity of human sera with overlapping synthetic peptides of herpes simplex virus type 1 glycoprotein D.

H J Geerligs1, M Feijlbrief, M Bolk, C A Bos, J W Drijfhout, G W Welling, S Welling-Wester.   

Abstract

Thirty eight human sera, seropositive for herpes simplex virus (HSV) and 56 human sera, seronegative for HSV by immunofluorescence and by ELISA, were investigated for reactivity with a series of overlapping synthetic peptides of HSV type 1 glycoprotein D (gD-1). Thirty four out of the 38 human sera positive for HSV reacted with peptides located between residues 300 and 369; the HSV-negative sera reacted with six of the gD-1 peptides, but with none of the peptides within residues 300 to 369.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173527     DOI: 10.1007/BF01310754

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Localization of epitopes of herpes simplex virus type 1 glycoprotein D.

Authors:  R J Eisenberg; D Long; M Ponce de Leon; J T Matthews; P G Spear; M G Gibson; L A Lasky; P Berman; E Golub; G H Cohen
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

3.  Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins.

Authors:  B R Eing; J E Kühn; R W Braun
Journal:  J Med Virol       Date:  1989-01       Impact factor: 2.327

4.  Structural properties and reactivity of N-terminal synthetic peptides of herpes simplex virus type 1 glycoprotein D by using antipeptide antibodies and group VII monoclonal antibodies.

Authors:  D L Bosch; H J Geerligs; W J Weijer; M Feijlbrief; G W Welling; S Welling-Wester
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

5.  Fine mapping of antigenic site II of herpes simplex virus glycoprotein D.

Authors:  V J Isola; R J Eisenberg; G R Siebert; C J Heilman; W C Wilcox; G H Cohen
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Letters to the editor: Correlation of conformation and biological activity in lysozyme "loop" homologs.

Authors:  R Arnon; E Teicher; H A Scheraga
Journal:  J Mol Biol       Date:  1974-12-05       Impact factor: 5.469

7.  Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody.

Authors:  G H Cohen; B Dietzschold; M Ponce de Leon; D Long; E Golub; A Varrichio; L Pereira; R J Eisenberg
Journal:  J Virol       Date:  1984-01       Impact factor: 5.103

8.  Antibodies against synthetic peptides of the B subunit of cholera toxin: crossreaction and neutralization of the toxin.

Authors:  C O Jacob; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

9.  Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli.

Authors:  R J Watson; J H Weis; J S Salstrom; L W Enquist
Journal:  Science       Date:  1982-10-22       Impact factor: 47.728

10.  Use of synthetic peptides to map the antigenic determinants of glycoprotein D of herpes simplex virus.

Authors:  N C Strynadka; M J Redmond; J M Parker; D G Scraba; R S Hodges
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

View more
  2 in total

1.  Detection of antibodies against equine herpesvirus types 1 and 4 by using recombinant protein derived from an immunodominant region of glycoprotein B.

Authors:  R Sinclair; M M Binns; E D Chirnside; J A Mumford
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

2.  T cell responses to synthetic peptides of herpes simplex virus type 1 glycoprotein D in naturally infected individuals.

Authors:  R A Damhof; J W Drijfhout; A J Scheffer; J B Wilterdink; G W Welling; S Welling-Wester
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.